mass spectrometry raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-12 and is reviewed periodically as new material appears.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
=== Bibliography === Amis, Martin (2000). Experience. Vintage. ISBN 978-0-099-28582-3. Blundell, Nigel (1996). Encyclopaedia of Serial Killers. Promotional Reprint Company Ltd. ISBN 978-1-856-48328-5. Burn, Gordon (1998). Happy Like Murderers. Faber and Faber (London). ISBN 978-0-571-19546-6. Carter Woodrow, Jane (2011). Rose West: The Making of a Monster. Hodder & Stoughton. ISBN 9781848946866. Cawthorne, Nigel (2007). Serial Killers and Mass Murderers: Profiles of the World's Most Barbaric Criminals. Ulysses Press. ISBN 978-1-569-75578-5. Cresswell, Kim (2016). Garden of Bones - The Story of Fred and Rosemary West. KC Publishing. ISBN 9780995057807. Roberts, Caroline (2005). The Lost Girl: How I Triumphed Over Life at the Mercy of Fred and Rose West. Metro Books (London). ISBN 978-1-84358-088-1. Sounes, Howard (1995). Fred and Rose: The Full Story of Fred and Rose West and the Gloucester House of Horrors. Warner Books (London). ISBN 978-0-7515-1322-6. Wansell, Geoffrey (1996). An Evil Love: The Life of Frederick West. Hodder Headline (London). ISBN 978-0-7472-1760-2. West, Anne Marie (1995). Out of the Shadows: Fred West's Daughter Tells Her Harrowing Story of Survival. Simon & Schuster. ISBN 978-0-671-71968-5. Wilson, Colin (1998). The Corpse Garden. True Crime Library (London). ISBN 978-1-874358-24-4. "Fred & Rosemary West". Murder in Mind. No. 1. 1996. ISSN 1364-5803.
=== Types of vitamin A === It is "largely impossible" for provitamin carotenoids, such as beta-carotene, to cause toxicity, as their conversion to retinol is highly regulated. No vitamin A toxicity has ever been reported from ingestion of excessive amounts. Overconsumption of beta-carotene can only cause carotenosis, a harmless and reversible cosmetic condition in which the skin turns orange. Preformed vitamin A absorption and storage in the liver occur very efficiently until a pathologic condition develops. When ingested, 70–90% of preformed vitamin A is absorbed.
amplicon Any DNA or RNA sequence or fragment that is the source and/or product of an amplification reaction. The term is most frequently used to describe the numerous copied fragments that are the products of the polymerase chain reaction or ligase chain reaction, though it may also refer to sequences that are amplified naturally within a genome, e.g. by gene duplication.
=== 1982 World's Fair === In 1974, Downtown Knoxville Association president Stewart Evans, following a discussion with King Cole, president of the 1974 Spokane Exposition, raised the possibility of a similar international exposition for Knoxville. Testerman and Tyree both embraced the fair, though the city council and Knoxvillians in general were initially lukewarm to the idea. One key supporter of the fair was rogue banker Jake Butcher, who in 1975 seized control of Knoxville's largest bank, Hamilton National, and shook up the city's conservative banking community. Following his failed gubernatorial campaign in 1978, Butcher turned his attention to the fair initiative, and helped the city raise critical funding. To prepare for the World's Fair, the merged stretch of I-40 and I-75 in West Knoxville was widened, and I-640 was constructed. The old L&N yard along Second Creek, home to a rough neighborhood known as "Scuffletown," was chosen for the fair site, largely for its redevelopment potential. Three hotel chains— Radisson, Hilton, and Holiday Inn— built large hotels in the downtown area in anticipation of the influx of fair visitors. The fair, officially named the International Energy Exposition, was open from May 1 to October 31, 1982, and drew over 11 million visitors. Its success defied the expectations of the Wall Street Journal, which had derided Knoxville as a "scruffy little town," and had predicted the fair would fail.
Sources: en.wikipedia.org
=== Growth over 1997–2010 === India in 1997 allowed foreign direct investment (FDI) in cash and carry wholesale. Then, it required government approval. The approval requirement was relaxed, and automatic permission was granted in 2006. Between 2000 and 2010, Indian retail attracted about $1.8 billion in foreign direct investment, representing a very small 1.5% of total investment flow into India. Single brand retailing attracted 94 proposals between 2006 and 2010, of which 57 were approved and implemented. For a country of 1.2 billion people, this is a very small number. Some claim one of the primary restraint inhibiting better participation was that India required single brand retailers to limit their ownership in Indian outlets to 51%. China in contrast allows 100% ownership by foreign companies in both single brand and multi-brand retail presence. Indian retail has experienced limited growth, and its spoilage of food harvest is amongst the highest in the world, because of very limited integrated cold chain and other infrastructure. India has only 5386 stand-alone cold storages, having a total capacity of 23.6 million metric tons. However, 80 percent of this storage is used only for potatoes. The remaining infrastructure capacity is less than 1% of the annual farm output of India, and grossly inadequate during peak harvest seasons. This leads to about 30% losses in certain perishable agricultural output in India, on average, every year. Indian laws already allow foreign direct investment in cold-chain infrastructure to the extent of 100 percent.
According to the World Database on Protected Areas, 37% of Belize's land territory falls under some form of official protection, giving Belize one of the most extensive systems of terrestrial protected areas in the Americas. By contrast, Costa Rica only has 27% of its land territory protected. Around 20.4% of Belize's marine and coastal areas, which contain the Belize Barrier Reef, are protected. The Belize Barrier Reef is a UNESCO-recognized World Heritage Site and is the second-largest barrier reef in the world, behind Australia's Great Barrier Reef. A remote sensing study conducted by the Water Center for the Humid Tropics of Latin America and the Caribbean (CATHALAC) and NASA, in collaboration with the Forest Department and the Land Information Centre (LIC) of the government of Belize's Ministry of Natural Resources and the Environment (MNRE), and published in August 2010 revealed that Belize's forest cover in early 2010 was approximately 62.7%, down from 75.9% in late 1980. A similar study by Belize Tropical Forest Studies and Conservation International revealed similar trends in terms of Belize's forest cover. Both studies indicate that each year, 0.6% of Belize's forest cover is lost, translating to the clearing of an average of 10,050 hectares (24,835 acres) each year. The USAID-supported SERVIR study by CATHALAC, NASA, and the MNRE also showed that Belize's protected areas have been extremely effective in protecting the country's forests.
== Prognosis and Epidemiology == Unfortunately, most conditions that cause eclabium, such as ichthyosis, have a very high mortality rate with worldwide figure approaching 50 percent. However, eclabium caused by improper wound healing is usually reversible through another corrective surgery and has little to no mortality. Scarring can occur from surgery to correct eclabium. Some patients might get further cosmetic surgery to fix the scarring. Eclabium caused by Periodontitis is almost always treatable and if it has advanced severely, surgery can help to treat it. It does not cause death but it can become very painful and decrease the quality of life if left untreated. It can affect anyone who does not follow good oral hygiene. It currently affects 20-50% of the global population but only a small portion of cases become severe enough to cause eclabium. Eclabium caused by harlequin ichthyosis is more severe. Its prognosis is very poor. Most affected babies do not survive the first week of life. Survival rates based on the severity of the case have varied from 10 months to 25 years with supportive treatment. The oldest person in the united states with Harlequin Ichthyosis is 23 year old Stephanie Turner. She was also the first person to have a child with this condition. She has two children and neither have the condition. There is a 25% chance of this condition reoccurring in the mothers next pregnancy. Genetic counseling is highly recommended for couples who have the mutated ABCA12 gene.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.